Saptarsi Haldar, MD, BS

Associate Investigator, Gladstone Institutes
Associate Professor of Medicine
Cardiovascular Division
+1 415 734-4058
Research Description: 

Clinical: I am a cardiologist specializing in general adult cardiology.

Primary Appointment: In 2018, I was recruited to be a Vice President of Research at Amgen, based in South San Francisco. I am the head of Cardiometabolic Research at Amgen, where I lead multidisciplinary efforts in drug discovery and development for a wide range of cardiovascular and metabolic diseases. I have maintained visiting faculty appointments at UCSF and Gladstone Institutes, where I continue to participate in mentorship, original research, volunteer clinical service and other academic activities.

Research: I am a Visiting Investigator at the Gladstone Institute of Cardiovascular Disease and a Visiting Professor the University of California, San Francisco. My scientific focus is to understand gene-regulatory and epigenetic mechanisms governing cell state transitions in the cardiovascular system and in skeletal muscle with an ultimate goal of finding novel therapeutic strategies to prevent and treat heart failure, cardiometabolic, and myopathic diseases.

A major focus of our team is in the pathobiology of heart failure, a devastating disease for which morbidity and mortality remain extremely high despite current standards of medical care. As a practicing physician-scientist that recognizes this major unmet need, one of my laboratory’s central goals is to discover novel mechanisms underlying heart failure pathogenesis and to develop new therapeutic strategies for this extremely common and lethal condition. We have a deep interest in the very nascent area of cardiovascular epigenetics and seek to unravel how chromatin-dependent signal transduction drives cardiovascular plasticity during physiological and pathophysiological states. As epigenetic regulators and chromatin-associated proteins are often tractable drug targets, we actively seek to translate our findings into novel transcriptionally-active cardiovascular therapeutics.

Primary Thematic Area: 
Vascular & Cardiac Biology
Secondary Thematic Area: 
Tissue / Organ Biology & Endocrinology
Research Summary: 
Gene Regulation and Epigenetics in Cardiovascular and Metabolic Physiology/Disease

Websites

Publications: 

Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling.

The Journal of clinical investigation

Hsu A, Duan Q, McMahon S, Huang Y, Wood SA, Gray NS, Wang B, Bruneau BG, Haldar SM

Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming.

JCI insight

Quattrocelli M, Zelikovich AS, Jiang Z, Peek CB, Demonbreun AR, Kuntz NL, Barish GD, Haldar SM, Bass J, McNally EM

Minimal in vivo requirements for developmentally regulated cardiac long intergenic non-coding RNAs.

Development (Cambridge, England)

George MR, Duan Q, Nagle A, Kathiriya IS, Huang Y, Rao K, Haldar SM, Bruneau BG

Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation.

Circulation research

Stratton MS, Bagchi RA, Felisbino MB, Hirsch RA, Smith HE, Riching AS, Enyart BY, Koch KA, Cavasin MA, Alexanian M, Song K, Qi J, Lemieux ME, Srivastava D, Lam MP, Haldar SM, Lin CY, McKinsey TA

Epigenetic therapies in heart failure.

Journal of molecular and cellular cardiology

Alexanian M, Padmanabhan A, McKinsey TA, Haldar SM